Please sign in to follow a disease.
Could a simple eyelid wipe soothe dry eyes?
NCT ID NCT07140380
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested three ways to use an eyelid wipe soaked with IVW-1001, a dry eye treatment, in 30 people with dry eye disease. Researchers measured changes in tear production and checked for any vision changes. The goal was to find the best wiping technique for safety and symptom relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- IVW-1001 ophthalmic eyelid wipe
- What this could lead to
- If it works, this could point toward a convenient wipe-based treatment to ease dry eye symptoms and boost tear production.
- What could go wrong
- This is a small, early proof-of-concept study with only 30 people. Results may not apply to everyone, and the wipe may not outperform existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
30 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Oct 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Self-reported diagnosis of DED in one or both eyes * BCVA +0.70 logarithm of minimum angle of refraction (Snellen equivalent 20/100) or better in each eye at the Screening Visit * For women of childbearing potential, confirmed negative pregnancy test at the Screening Visit, not nursing a child, and willing to comply with one of the acceptable methods of birth control described in the protocol * History (by subject recollection) of artificial tear use within 30 days prior to the Screening Visit * Unanesthetized Schirmer's test score 5-19 mm inclusive in at least 1 eye (same eye) at the Screening Visit and the Baseline Visit Exclusion Criteria: * Corneal fluorescein staining score of 4 in either eye in any zone using the National Eye Institute grading system at either the Screening Visit or the Baseline Visit * IOP ≥23 mmHg in either eye at either the Screening Visit or the Baseline Visit * History of glaucoma or ocular hypertension in either eye requiring past or current medical or surgical intervention
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dry eye disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eye Research Foundation
Newport Beach, California, 92663, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two eye gels go head to head for dry eye relief
- Can a new eyedrop heal the cornea in dry eye disease?
- Can a daily eye drop safely treat dry eye? phase 3 trial puts tivanisiran to the test
- Can tiny fat bubbles in eye drops soothe dry eyes?
- Can a new eye drop fully clear dry eye redness?
- Could a common dry eye drop shield the Cornea's inner layer?